Intended for healthcare professionals

Feature

Commentary: NHS patients should have a choice of drug for wet age-related macular degeneration, despite pressure from pharma

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5013 (Published 01 November 2017) Cite this as: BMJ 2017;359:j5013

Re: Commentary: NHS patients should have a choice of drug for wet age-related macular degeneration, despite pressure from pharma

CCGs are frequently in the news, and are criticised, for 'rationing' certain treatments on spurious grounds. These 12 CCGs should be lauded for increasing patient choice to include Avastin for wet AMD. Many will choose the cheapest option, for altruistic reasons, and big pharma would be unwise to prevent them doing so. As I asked when the issue was last raised here, why are Health Ministers and the UK CMOs silent?

Competing interests: No competing interests

01 November 2017
John G Gooderham
locum lollipop lady
none
Billingshurst